AudioScholar Oncology Weekly

AudioScholar
  • 0.0 (0)
  • Medicine
  • Updated Weekly

Oncology — a weekly podcast briefing of the most significant peer-reviewed oncology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

  1. 1d ago

    This Week in Oncology — Aug 19, 2026

    Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning long-term outcomes and biomarker refinement in hormone-driven cancers, resistance and new drug platforms in oncogene-driven lung cancer, chemotherapy-free strategie… This week's papers: 1. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3 — Journal of Clinical Oncology 2026 2. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2 — Journal of Clinical Oncology 2026 3. EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology — Clinical Cancer Research 2026 4. Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET;… — Annals of Oncology 2026 5. Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive, HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) — Annals of Oncology 2026 6. Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer — Annals of Oncology 2026 7. Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma — Journal of Clinical Oncology 2026 8. BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies — Clinical Cancer Research 2026 9. SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial — Cancer Cell 2026 10. A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer — Clinical Cancer Research 2026 Listen at https://audioscholar.cc/episode/ef9htvxqas

  2. Aug 12

    This Week in Oncology — Aug 12, 2026

    Welcome to This Week in Oncology. This week we're covering 9 notable papers spanning treatment intensification in advanced solid tumours, biomarker-guided and antibody-drug conjugate strategies, and the growing evidence base for supportive care and l… This week's papers: 1. [Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, contr… — The Lancet 2026 2. Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial — JAMA 2026 3. Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase II… — Journal of Clinical Oncology 2026 4. SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Con… — Annals of Oncology 2026 5. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results… — Annals of Oncology 2026 6. Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial — JAMA Oncology 2026 7. Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low HER2 Expression — Journal of Clinical Oncology 2026 8. Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2 — Journal of Clinical Oncology 2026 9. Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia — Journal of Clinical Oncology 2026 Listen at https://audioscholar.cc/episode/dtsrweq9u3

  3. Aug 6

    This Week in Oncology — Aug 5, 2026

    Welcome to This Week in Oncology. This week we're covering 7 notable papers spanning supportive care and de-escalation, biomarker-driven treatment selection across solid tumours, and rare cancers with long-term outcome data. Let's dive in. We start… This week's papers: 1. Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial… — Journal of Clinical Oncology 2026 2. Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703) — JAMA 2026 3. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study — Journal of Clinical Oncology 2026 4. Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study — Journal of Clinical Oncology 2026 5. Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial — Journal of Clinical Oncology 2026 6. High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation — Journal of Clinical Oncology 2026 7. Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial — Clinical Cancer Research 2026 Listen at https://audioscholar.cc/episode/3ntyzzvrt2

  4. Jul 31

    This Week in Oncology — Jul 31, 2026

    Welcome to This Week in Oncology. This week we're covering 7 notable papers spanning localized therapy optimization, neoadjuvant immunotherapy combinations, and precision oncology insights. Let's dive in. Optimizing localized therapies while minimiz… This week's papers: 1. Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial — JAMA Oncology 2026 2. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial — JAMA Oncology 2026 3. Feasibility and activity of concurrent neoadjuvant chemotherapy and radiation therapy in patients with high-risk soft tissue sarcoma — Clinical Cancer Research 2026 4. Microsatellite Instability Identifies a Rare but Clinically Relevant Subset of Sarcomas: Insights from the Largest Clinically Sequenced Cohort with Therapeutic… — Clinical Cancer Research 2026 5. Investigation of a prostate cancer radiation response signature in the breast cancer SweBCG91RT randomized trial — Clinical Cancer Research 2026 6. "SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal? — Clinical Cancer Research 2026 7. Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study — Clinical Cancer Research 2026 Listen at https://audioscholar.cc/episode/7fwbppcdx8

  5. Jul 22

    This Week in Oncology — Jul 22, 2026

    Welcome to This Week in Oncology. This week we're covering 5 notable papers spanning biomarker-driven immunotherapy, cellular therapy in gastrointestinal malignancy, antibody-drug conjugate mechanisms, and management of opportunistic fungal infection… This week's papers: 1. Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer. — Clinical Cancer Research 2026 2. Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity. — Clinical Cancer Research 2026 3. Non-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer. — Clinical Cancer Research 2026 4. Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study. — Annals of Internal Medicine 2026 Listen at https://audioscholar.cc/episode/xbnb6mhawz

  6. Jul 15

    This Week in Oncology — Jul 15, 2026

    Welcome to This Week in Oncology. This week we are covering ten notable papers spanning targeted therapeutic strategies in solid tumors, proactive management of resistance in breast and gynecologic malignancies, new insights into hematologic treatmen… This week's papers: 1. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. — Journal of Clinical Oncology 2026 2. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer… — The Lancet. Oncology 2026 3. Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial. — The Lancet. Oncology 2026 4. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. — Journal of Clinical Oncology 2026 5. Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. — Journal of Clinical Oncology 2026 6. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. — Journal of Clinical Oncology 2026 7. Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. — Journal of Clinical Oncology 2026 8. Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib. — Clinical Cancer Research 2026 9. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Communi… — Journal of Clinical Oncology 2026 10. An anti-PMEL antibody-drug conjugate with a Ginhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial. — Nature Medicine 2026 Listen at https://audioscholar.cc/episode/7ckam86ed7

  7. Jul 9

    This Week in Oncology — Jul 9, 2026

    Welcome to This Week in Oncology. This week we are covering four notable papers spanning novel therapeutic boundaries in thoracic oncology, the limits of aggressive regional interventions in gastric cancer, and the evolving systemic landscape of adva… This week's papers: 1. Ensartinib in Resected-Positive Non-Small-Cell Lung Cancer — The New England journal of medicine 2026 2. Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limit… — The Lancet. Oncology 2026 3. Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer — JAMA 2026 4. Advances in systemic therapies for advanced prostate cancer — BMJ 2026 Listen at https://audioscholar.cc/episode/rz9q9z77ck

  8. Jul 1

    This Week in Oncology — Jul 1, 2026

    Welcome to This Week in Oncology. This week we are covering ten notable papers spanning breast cancer treatment optimization, the limits of local treatment intensification, and emerging combined-modality therapies for advanced malignancies. Let us di… This week's papers: 1. Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial — The Lancet. Oncology 2026 2. Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBIT… — The Lancet. Oncology 2026 3. Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial — The Lancet. Oncology 2026 4. Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis o… — The Lancet. Oncology 2026 5. Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospe… — The Lancet. Oncology 2026 6. SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned ove… — The Lancet. Oncology 2026 7. Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative G… — The Lancet. Oncology 2026 8. European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium,… — The Lancet. Oncology 2026 9. Claudin 18.2 Targeting: A Pan-Cancer Perspective — Clinical Cancer Research 2026 Listen at https://audioscholar.cc/episode/j7kxhsexvv

See All (15)

About

Oncology — a weekly podcast briefing of the most significant peer-reviewed oncology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Information